30Oct
[Video] I Wish I Knew What I Know Now: Conversations with AGG on FDA Issues - Key Due Diligence Issues to Consider When Acquiring or Investing in Life Sciences Companies or Products
AGG is pleased to present the second episode in a podcast series titled, “I Wish I Know What I Know Now: Conversations with AGG on FDA Issues,” covering key due diligence issues to consider when acquiring or investing in life science companies or products. In this episode, AGG partner Alan G. Minsk and Brian A. Teras provides an overview of the diligence process, potential red flags, common mistakes, and other factors to consider during the due diligence process. Each month, we'll release a...
By:
Arnall Golden Gregory LLP
Related
In Fort Bend County, Texas v. Davis, the Supreme Court of the United States held that the requiremen...
Read More >
In collective actions under the FLSA, courts typically apply a lower standard to the first “conditi...
Read More >
The Australian government has introduced the most significant reforms to Australia’s foreign invest...
Read More >
The impact of COVID-19, the ensuing delays and changes in the work, protecting the contractor’s cas...
Read More >
Last Friday, I had the opportunity to talk about Artificial Intelligence in the Workplace at the CBI...
Read More >
Climate-related disclosures for asset managers and FCA-regulated pension schemes: FCA correspondence...
Read More >